---
document_datetime: 2025-12-02 04:53:39
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/litfulo.html
document_name: litfulo.html
version: success
processing_time: 0.1070636
conversion_datetime: 2025-12-28 01:12:41.395117
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Litfulo

[RSS](/en/individual-human-medicine.xml/67711)

##### Authorised

This medicine is authorised for use in the European Union

ritlecitinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Litfulo](#news-on)
- [More information on Litfulo](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Litfulo is a medicine used to treat adults and adolescents over 12 years of age with severe alopecia areata, an autoimmune disease (a disease caused by the body's own defence system attacking normal tissue) causing hair loss of the scalp or other parts of the body.

Litfulo contains the active substance ritlecitinib.

Expand section

Collapse section

## How is Litfulo used?

Litfulo can only be obtained with a prescription and treatment must be started and supervised by a doctor experienced in the diagnosis and treatment of alopecia areata.

Litfulo is available as capsules taken by mouth once a day. Treatment should be interrupted or stopped if patients experience serious infections or low blood cell levels. Treatment should be stopped if no improvements are seen after 36 weeks.

For more information about using Litfulo, see the package leaflet or contact your doctor or pharmacist.

## How does Litfulo work?

In people with alopecia areata, the immune system attacks the hair follicles and causes hair growth to slow or stop altogether, leading to hair loss. The active substance in Litfulo, ritlecitinib, is an immunosuppressant (a medicine that reduces the activity of the immune system). It works by blocking the action of certain enzymes called JAK3 and TEC kinases, which play an important role in inflammation. By blocking these enzymes, ritlecitinib reduces inflammation, allowing hair regrowth in people with alopecia areata.

## What benefits of Litfulo have been shown in studies?

The benefits of Litfulo were investigated in a main study involving 718 adults and adolescents over 12 years of age with severe alopecia areata, 261 of whom were given 50 mg Litfulo or placebo (a dummy treatment). All patients had more than 50% hair loss on the scalp before they started treatment. After 24 weeks of treatment, disease symptoms improved in patients given Litfulo: 13% of them were in near remission, meaning that they had more than 90% hair coverage on their scalp, and 23% had more than 80% hair coverage. Such improvements were seen in 1.5% of patients given placebo. After 48 weeks, 31% of patients given Litfulo were in near remission. When asked whether their alopecia had improved, 49% of patients given Litfulo stated that their condition had moderately or greatly improved, compared with 9% of patients given placebo.

## What are the risks associated with Litfulo?

For the full list of side effects and restrictions with Litfulo, see the package leaflet.

The most common side effects with Litfulo (which may affect up to 1 in 10 people) include diarrhoea, acne, upper respiratory tract (nose and throat) infections, urticaria (itchy rash), rash, folliculitis (inflammation of hair follicles) and dizziness.

Litfulo must not be used in patients with active serious infections, including tuberculosis, or severe liver problems. The medicine also must not be used in women who are pregnant or breast-feeding.

## Why is Litfulo authorised in the EU?

Litfulo was shown to be effective in the treatment of severe alopecia areata in adults and adolescents, and the benefits were maintained over time. Although the side effects of Litfulo are considered manageable, there are uncertainties regarding long-term use due to limited data. Several measures have been put in place to minimise risks associated with Litfulo.

Given the importance of scalp hair regrowth for patients with severe alopecia areata, the European Medicines Agency decided that Litfulo's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Litfulo?

The company that markets Litfulo must provide educational materials to healthcare professionals and patients with information on the safety of the medicine, specifically regarding the risk of infections, cardiovascular conditions (diseases affecting the heart or blood vessels), cancer, neurotoxicity (damage to the nervous system) and toxicity to the unborn baby when exposed during pregnancy.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Litfulo have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Litfulo are continuously monitored. Suspected side effects reported with Litfulo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Litfulo

Litfulo received a marketing authorisation valid throughout the EU on 15 September 2023.

Litfulo : EPAR - Medicine Overview

Reference Number: EMA/342745/2023

English (EN) (122.02 KB - PDF)

**First published:** 18/09/2023

[View](/en/documents/overview/litfulo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-393)

български (BG) (147.21 KB - PDF)

**First published:**

18/09/2023

[View](/bg/documents/overview/litfulo-epar-medicine-overview_bg.pdf)

español (ES) (122.18 KB - PDF)

**First published:**

18/09/2023

[View](/es/documents/overview/litfulo-epar-medicine-overview_es.pdf)

čeština (CS) (144.62 KB - PDF)

**First published:**

18/09/2023

[View](/cs/documents/overview/litfulo-epar-medicine-overview_cs.pdf)

dansk (DA) (121.07 KB - PDF)

**First published:**

18/09/2023

[View](/da/documents/overview/litfulo-epar-medicine-overview_da.pdf)

Deutsch (DE) (125.32 KB - PDF)

**First published:**

18/09/2023

[View](/de/documents/overview/litfulo-epar-medicine-overview_de.pdf)

eesti keel (ET) (119.13 KB - PDF)

**First published:**

18/09/2023

[View](/et/documents/overview/litfulo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (143.94 KB - PDF)

**First published:**

18/09/2023

[View](/el/documents/overview/litfulo-epar-medicine-overview_el.pdf)

français (FR) (123.82 KB - PDF)

**First published:**

18/09/2023

[View](/fr/documents/overview/litfulo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.7 KB - PDF)

**First published:**

18/09/2023

[View](/hr/documents/overview/litfulo-epar-medicine-overview_hr.pdf)

italiano (IT) (120.2 KB - PDF)

**First published:**

18/09/2023

[View](/it/documents/overview/litfulo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (152.64 KB - PDF)

**First published:**

18/09/2023

[View](/lv/documents/overview/litfulo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (143.58 KB - PDF)

**First published:**

18/09/2023

[View](/lt/documents/overview/litfulo-epar-medicine-overview_lt.pdf)

magyar (HU) (145.4 KB - PDF)

**First published:**

18/09/2023

[View](/hu/documents/overview/litfulo-epar-medicine-overview_hu.pdf)

Malti (MT) (147.14 KB - PDF)

**First published:**

18/09/2023

[View](/mt/documents/overview/litfulo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (122.74 KB - PDF)

**First published:**

18/09/2023

[View](/nl/documents/overview/litfulo-epar-medicine-overview_nl.pdf)

polski (PL) (146.43 KB - PDF)

**First published:**

18/09/2023

[View](/pl/documents/overview/litfulo-epar-medicine-overview_pl.pdf)

português (PT) (123.32 KB - PDF)

**First published:**

18/09/2023

[View](/pt/documents/overview/litfulo-epar-medicine-overview_pt.pdf)

română (RO) (142.48 KB - PDF)

**First published:**

18/09/2023

[View](/ro/documents/overview/litfulo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.55 KB - PDF)

**First published:**

18/09/2023

[View](/sk/documents/overview/litfulo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (141.39 KB - PDF)

**First published:**

18/09/2023

[View](/sl/documents/overview/litfulo-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.84 KB - PDF)

**First published:**

18/09/2023

[View](/fi/documents/overview/litfulo-epar-medicine-overview_fi.pdf)

svenska (SV) (120.23 KB - PDF)

**First published:**

18/09/2023

[View](/sv/documents/overview/litfulo-epar-medicine-overview_sv.pdf)

Litfulo : EPAR - Risk Management Plan

English (EN) (1.45 MB - PDF)

**First published:** 18/09/2023

**Last updated:** 03/03/2025

[View](/en/documents/rmp/litfulo-epar-risk-management-plan_en.pdf)

## Product information

Litfulo : EPAR - Product Information

English (EN) (288.74 KB - PDF)

**First published:** 18/09/2023

**Last updated:** 27/02/2025

[View](/en/documents/product-information/litfulo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-411)

български (BG) (309.88 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/bg/documents/product-information/litfulo-epar-product-information_bg.pdf)

español (ES) (308.82 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/es/documents/product-information/litfulo-epar-product-information_es.pdf)

čeština (CS) (283.44 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/cs/documents/product-information/litfulo-epar-product-information_cs.pdf)

dansk (DA) (310.34 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/da/documents/product-information/litfulo-epar-product-information_da.pdf)

Deutsch (DE) (290.17 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/de/documents/product-information/litfulo-epar-product-information_de.pdf)

eesti keel (ET) (306.07 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/et/documents/product-information/litfulo-epar-product-information_et.pdf)

ελληνικά (EL) (346.5 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/el/documents/product-information/litfulo-epar-product-information_el.pdf)

français (FR) (302.88 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/fr/documents/product-information/litfulo-epar-product-information_fr.pdf)

hrvatski (HR) (292.89 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/hr/documents/product-information/litfulo-epar-product-information_hr.pdf)

íslenska (IS) (298.16 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/is/documents/product-information/litfulo-epar-product-information_is.pdf)

italiano (IT) (272.63 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/it/documents/product-information/litfulo-epar-product-information_it.pdf)

latviešu valoda (LV) (323.96 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/lv/documents/product-information/litfulo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (287.02 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/lt/documents/product-information/litfulo-epar-product-information_lt.pdf)

magyar (HU) (309.83 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/hu/documents/product-information/litfulo-epar-product-information_hu.pdf)

Malti (MT) (322.68 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/mt/documents/product-information/litfulo-epar-product-information_mt.pdf)

Nederlands (NL) (287.25 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/nl/documents/product-information/litfulo-epar-product-information_nl.pdf)

norsk (NO) (277.59 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/no/documents/product-information/litfulo-epar-product-information_no.pdf)

polski (PL) (308.54 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/pl/documents/product-information/litfulo-epar-product-information_pl.pdf)

português (PT) (281.36 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/pt/documents/product-information/litfulo-epar-product-information_pt.pdf)

română (RO) (402.82 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/ro/documents/product-information/litfulo-epar-product-information_ro.pdf)

slovenčina (SK) (306.29 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/sk/documents/product-information/litfulo-epar-product-information_sk.pdf)

slovenščina (SL) (273.46 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/sl/documents/product-information/litfulo-epar-product-information_sl.pdf)

Suomi (FI) (279.45 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/fi/documents/product-information/litfulo-epar-product-information_fi.pdf)

svenska (SV) (432.06 KB - PDF)

**First published:**

18/09/2023

**Last updated:**

27/02/2025

[View](/sv/documents/product-information/litfulo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** N/0000245562 26/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Litfulo : EPAR - All authorised presentations

English (EN) (25.23 KB - PDF)

**First published:** 18/09/2023

[View](/en/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-144)

български (BG) (29.01 KB - PDF)

**First published:**

18/09/2023

[View](/bg/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_bg.pdf)

español (ES) (26.44 KB - PDF)

**First published:**

18/09/2023

[View](/es/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (28.2 KB - PDF)

**First published:**

18/09/2023

[View](/cs/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (27.24 KB - PDF)

**First published:**

18/09/2023

[View](/da/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (27.02 KB - PDF)

**First published:**

18/09/2023

[View](/de/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (26.84 KB - PDF)

**First published:**

18/09/2023

[View](/et/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (28.25 KB - PDF)

**First published:**

18/09/2023

[View](/el/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_el.pdf)

français (FR) (25.84 KB - PDF)

**First published:**

18/09/2023

[View](/fr/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (25.79 KB - PDF)

**First published:**

18/09/2023

[View](/hr/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (24.55 KB - PDF)

**First published:**

18/09/2023

[View](/is/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (25.49 KB - PDF)

**First published:**

18/09/2023

[View](/it/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (26.52 KB - PDF)

**First published:**

18/09/2023

[View](/lv/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (27.61 KB - PDF)

**First published:**

18/09/2023

[View](/lt/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (27.75 KB - PDF)

**First published:**

18/09/2023

[View](/hu/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (27.24 KB - PDF)

**First published:**

18/09/2023

[View](/mt/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (26.88 KB - PDF)

**First published:**

18/09/2023

[View](/nl/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (26.48 KB - PDF)

**First published:**

18/09/2023

[View](/no/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_no.pdf)

polski (PL) (27.06 KB - PDF)

**First published:**

18/09/2023

[View](/pl/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_pl.pdf)

português (PT) (26.15 KB - PDF)

**First published:**

18/09/2023

[View](/pt/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_pt.pdf)

română (RO) (26.12 KB - PDF)

**First published:**

18/09/2023

[View](/ro/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (27.62 KB - PDF)

**First published:**

18/09/2023

[View](/sk/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.47 KB - PDF)

**First published:**

18/09/2023

[View](/sl/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (25.45 KB - PDF)

**First published:**

18/09/2023

[View](/fi/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (26.05 KB - PDF)

**First published:**

18/09/2023

[View](/sv/documents/all-authorised-presentations/litfulo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Litfulo Active substance ritlecitinib tosilate International non-proprietary name (INN) or common name ritlecitinib Therapeutic area (MeSH) Alopecia Areata Anatomical therapeutic chemical (ATC) code L04AF08

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

## Authorisation details

EMA product number EMEA/H/C/006025

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 20/07/2023 Marketing authorisation issued 15/09/2023 Revision 5

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Litfulo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (140.96 KB - PDF)

**First published:** 27/02/2025

[View](/en/documents/procedural-steps-after/litfulo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Litfulo : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (148.58 KB - PDF)

**First published:** 06/06/2024

**Last updated:** 03/03/2025

[View](/en/documents/procedural-steps-after/litfulo-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Litfulo-H-C-006025-P46-006 : EPAR - Assessment report

Adopted

Reference Number: EMA/141622/2024

English (EN) (1.33 MB - PDF)

**First published:** 11/06/2024

[View](/en/documents/variation-report/litfulo-h-c-006025-p46-006-epar-assessment-report_en.pdf)

## Initial marketing authorisation documents

Litfulo : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/357337/2023

English (EN) (6.66 MB - PDF)

**First published:** 18/09/2023

[View](/en/documents/assessment-report/litfulo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Litfulo

Adopted

Reference Number: EMA/CHMP/328223/2023

English (EN) (137.24 KB - PDF)

**First published:** 21/07/2023

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-litfulo_en.pdf)

#### News on Litfulo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2023](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2023) 21/07/2023

#### More information on Litfulo

- [EMEA-002451-PIP01-18-M02 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002451-pip01-18-m02)
- [Prospective, Registry-Based Observational Cohort Study of Ritlecitinib Safety in Pregnancy - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000296)
- [A Prospective Active Surveillance Study to Monitor the Real-World Safety of Ritlecitinib Among Adolescents with Alopecia Areata - post-authorisation study](https://catalogues.ema.europa.eu/study/1000000421)

**This page was last updated on** 03/03/2025

## Share this page

[Back to top](#main-content)